MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Cadence is a placebo-controlled, randomised, double-blind trial assessing Winrevair’s safety and efficacy in CpcPH patients.

MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...

MSD (known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada) is collaborating with hospitals in Hanoi and Ho Chi Minh City to hold a series of scientific seminars titled “Updates ...

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...

Merck Sharp & Dohme (MSD), a global leader in infectious diseases, vaccines, and oncology, is going to celebrate its 25th anniversary in Vietnam next year. Already preparing for the occasion, Koen C.

LLC) in the Philippines, a subsidiary of the global biopharmaceutical company Merck & Co., Inc., officially launched “Gen V: Your Vibe, Your Move,” a youth-driven movement designed to boost education ...

In a year where ADC deals have showed no signs of slowing, Solve has become the latest biotech to unlock an extra slice of ...

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...